JP2018501195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501195A5 JP2018501195A5 JP2017524040A JP2017524040A JP2018501195A5 JP 2018501195 A5 JP2018501195 A5 JP 2018501195A5 JP 2017524040 A JP2017524040 A JP 2017524040A JP 2017524040 A JP2017524040 A JP 2017524040A JP 2018501195 A5 JP2018501195 A5 JP 2018501195A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- myh
- mes
- group
- functional variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims description 7
- 108010079505 Endostatins Proteins 0.000 claims description 7
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 4
- 230000000378 dietary effect Effects 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 210000001789 adipocyte Anatomy 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410610777 | 2014-11-03 | ||
| CN201410610777.X | 2014-11-03 | ||
| CN201510021469 | 2015-01-15 | ||
| CN201510021469.8 | 2015-01-15 | ||
| PCT/CN2015/093726 WO2016070798A1 (zh) | 2014-11-03 | 2015-11-03 | 一种抑制脂肪细胞分化和胰岛素耐受的药物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020126891A Division JP7227197B2 (ja) | 2014-11-03 | 2020-07-27 | 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018501195A JP2018501195A (ja) | 2018-01-18 |
| JP2018501195A5 true JP2018501195A5 (enExample) | 2018-12-13 |
Family
ID=55908589
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017524040A Pending JP2018501195A (ja) | 2014-11-03 | 2015-11-03 | 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物 |
| JP2020126891A Active JP7227197B2 (ja) | 2014-11-03 | 2020-07-27 | 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020126891A Active JP7227197B2 (ja) | 2014-11-03 | 2020-07-27 | 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20180015148A1 (enExample) |
| EP (1) | EP3246043A4 (enExample) |
| JP (2) | JP2018501195A (enExample) |
| CN (2) | CN107148277B (enExample) |
| AU (1) | AU2015342324B2 (enExample) |
| CA (1) | CA3003760A1 (enExample) |
| WO (1) | WO2016070798A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016127948A1 (zh) * | 2015-02-13 | 2016-08-18 | 清华大学 | 一种重组蛋白质药物的分子设计 |
| WO2018086603A1 (zh) | 2016-11-10 | 2018-05-17 | 北京普罗吉生物科技发展有限公司 | 聚乙二醇化血管内皮抑制素类似物及其应用 |
| US10276161B2 (en) | 2016-12-27 | 2019-04-30 | Google Llc | Contextual hotwords |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69824750T2 (de) * | 1997-10-31 | 2005-07-07 | Children's Medical Center Corp., Boston | Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe |
| CA2458047A1 (en) * | 2001-09-07 | 2003-03-20 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| US7524811B2 (en) * | 2003-08-29 | 2009-04-28 | Children's Medical Center Corporation | Anti-angiogenic peptides from the N-terminus of endostatin |
| CN101596320B (zh) * | 2006-01-20 | 2013-01-09 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
| CN103083681A (zh) * | 2006-01-20 | 2013-05-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
| EP2214709A4 (en) * | 2007-11-08 | 2011-05-11 | Univ Utah Res Found | USE OF ANGIOGENESIS ANTAGONISTS IN DISEASES WITH ANOMAL VENEER PREPARATION |
| CN101219206A (zh) * | 2008-02-01 | 2008-07-16 | 山东先声麦得津生物制药有限公司 | 重组人血管内皮抑制素在制药中的应用 |
| CN102698270B (zh) * | 2011-03-28 | 2016-02-03 | 清华大学 | 一种增强靶细胞摄取治疗剂的方法和药物组合物 |
| SG193317A1 (en) * | 2011-03-30 | 2013-10-30 | Univ Texas | Methods and compositions for targeting adipose cells in mammals |
| WO2013034116A1 (zh) * | 2011-09-09 | 2013-03-14 | 清华大学 | 对atp结合位点进行突变的血管内皮抑制素突变体 |
-
2015
- 2015-11-03 CA CA3003760A patent/CA3003760A1/en active Pending
- 2015-11-03 AU AU2015342324A patent/AU2015342324B2/en active Active
- 2015-11-03 CN CN201580059881.7A patent/CN107148277B/zh active Active
- 2015-11-03 WO PCT/CN2015/093726 patent/WO2016070798A1/zh not_active Ceased
- 2015-11-03 JP JP2017524040A patent/JP2018501195A/ja active Pending
- 2015-11-03 US US15/524,094 patent/US20180015148A1/en not_active Abandoned
- 2015-11-03 EP EP15857606.6A patent/EP3246043A4/en active Pending
- 2015-11-03 CN CN202210191378.9A patent/CN114558111A/zh active Pending
-
2020
- 2020-07-27 JP JP2020126891A patent/JP7227197B2/ja active Active
-
2022
- 2022-07-20 US US17/869,348 patent/US20220409703A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016540785A5 (enExample) | ||
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| JP2015078220A5 (enExample) | ||
| EP4632075A3 (en) | Method for reducing immunogenicity of rna | |
| JP2013520405A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| WO2015044292A8 (en) | Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease | |
| JP2015057451A5 (enExample) | ||
| JP2017532343A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2014198723A5 (enExample) | ||
| CN110114083A (zh) | 一种预防和治疗脂肪肝的方法 | |
| JP2015502389A5 (enExample) | ||
| HRP20210780T1 (hr) | Pripravci koji sadrže bakterijske sojeve | |
| JP2018521007A5 (enExample) | ||
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| JP2018501195A5 (enExample) | ||
| CN109689652A (zh) | 稠杂环类衍生物、其制备方法及其在医学上的应用 | |
| PH12015500653B1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| JP2018199643A5 (enExample) | ||
| JP2019500379A5 (enExample) | ||
| JP2019529569A5 (enExample) | ||
| CN107148277A (zh) | 一种抑制脂肪细胞分化和胰岛素耐受的药物 | |
| JP2016501208A5 (enExample) |